{Reference Type}: Journal Article
{Title}: Levamisole in childhood idiopathic nephrotic syndrome: new promises, and advocacy for global access.
{Author}: Chan EY;Boyer O;
{Journal}: Kidney Int
{Volume}: 105
{Issue}: 5
{Year}: 2024 May
{Factor}: 18.998
{DOI}: 10.1016/j.kint.2024.01.030
{Abstract}: In the current issue of Kidney International, Sinha et al. present data from an open-label, noninferior, randomized controlled trial comparing 12-months of alternate-day prednisolone, given daily during infection, versus levamisole, in children with frequently relapsing or steroid-dependent nephrotic syndrome. This study suggests that both of these strategies are efficacious and safe. Results of this study should redefine the role of levamisole in future guidelines, and a call for global availability of levamisole should be advocated.